Önder Arslan

Önder Arslan

Auto-generated profile, based on publicly available information

Önder Arslan

Department of Hematology, School of Medicine, Ankara University, Ankara, Türkiye

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2024 in LLM Dergi
Verified
Journal Article
Closed access
DKDerya Koyun
Derya Koyun
BABerna Ateşağaoğlu
Berna Ateşağaoğlu
SYSeher Yüksel
Seher Yüksel
GSGuldane Cengiz Seval
Guldane Cengiz Seval
SBSinem Civriz Civriz Bozdag
Sinem Civriz Civriz Bozdag
MÖMuhit Özcan
Muhit Özcan

2 June 2026 in Turkish Journal of Hematology
Verified
Journal Article
Open access
DKDerya Koyun
Derya Koyun
UŞUğur Şahin
Uğur Şahin
GSGuldane Cengiz Seval
Guldane Cengiz Seval
DGDeniz Gören
Deniz Gören
AGAyla Gökmen
Ayla Gökmen
MÖMuhit Özcan
Muhit Özcan
AlloHCT remains a curative option for R/R Hodgkin lymphoma despite advances with BV and CPIs. This study evaluates its role and outcomes in this challenging patient population. This retrospective oligocentric analysis involved 70 patients with R/R classical HL who underwent alloHCT. Patients were split into two treatment cohorts: era1 (2004-2010), 16 patients, and era2 (2011-2021), 54 patients. Among the cohort, sixty-three patients had previously received an autologous stem cell transplant. Forty patients were administered only (n=29) BV or BV preceding CPI (n=11) before alloHCT. A median follow-up of 64 months (40.7-87.3) revealed a 100-day non-relapse mortality (NRM) rate of 26%, with the 3-year overall survival (OS) and progression-free survival (PFS) reported as 39% and 28%, respectively. AlloHCT using haplotype-matched donors was linked to better OS and PFS. Post-transplant cyclophosphamide (post-tx CY) as a prophylactic approach for graft versus host disease (GVHD) significantly improved OS and PFS. A complete response (CR) during the post-transplant phase significantly improved OS and PFS. Indeed, better OS, PFS, and a reduced rate of NRM were observed in the pre/post-alloHCT BV and CPI group, although we could not demonstrate statistical significance. The survival (OS, PFS) curves and NRM rates were similar for both eras. AlloHCT is a potentially practical therapeutic approach in responding to R/R HL patients.

17 December 2021 in Journal of Ankara University Faculty of Medicine
Verified
Journal Article
Closed access
ZÖZehra Narlı Özdemir
Zehra Narlı Özdemir
UŞUğur Şahin
Uğur Şahin
SBSinem Civriz Civriz Bozdag
Sinem Civriz Civriz Bozdag
MYMeltem Kurt Yüksel
Meltem Kurt Yüksel
STSelami Koçak Toprak
Selami Koçak Toprak
OIOsman İlHan
Osman İlHan


14 May 2020 in Journal of Ankara University Faculty of Medicine
Verified
Journal Article
Closed access
PAPınar Ataca Atilla
Pınar Ataca Atilla
EAErden Atilla
Erden Atilla
EKEkin Kırcalı
Ekin Kırcalı
PTPervin Topçuoğlu
Pervin Topçuoğlu
TDTaner Demirer
Taner Demirer
STSelami Koçak Toprak
Selami Koçak Toprak

15 October 2020 in LLM Dergi
Verified
Journal Article
Closed access
EKEkin Kırcalı
Ekin Kırcalı
GSGuldane Cengiz Seval
Guldane Cengiz Seval
SBSinem Civriz Civriz Bozdag
Sinem Civriz Civriz Bozdag
MYMeltem Kurt Yüksel
Meltem Kurt Yüksel
PTPervin Topçuoğlu
Pervin Topçuoğlu
STSelami Koçak Toprak
Selami Koçak Toprak